- Home
- ABLV vs LTRN Comparison
ABLV vs LTRN Comparison
Compare ABLV & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABLV
- LTRN
- Stock Information
- Founded
- ABLV 2015
- LTRN 2013
- Country
- ABLV China
- LTRN United States
- Employees
- ABLV N/A
- LTRN N/A
- Industry
- ABLV
- LTRN Biotechnology: Pharmaceutical Preparations
- Sector
- ABLV
- LTRN Health Care
- Exchange
- ABLV Nasdaq
- LTRN Nasdaq
- Market Cap
- ABLV 38.1M
- LTRN 33.7M
- IPO Year
- ABLV N/A
- LTRN 2020
- Fundamental
- Price
- ABLV $1.10
- LTRN $4.81
- Analyst Decision
- ABLV
- LTRN Hold
- Analyst Count
- ABLV 0
- LTRN 1
- Target Price
- ABLV N/A
- LTRN N/A
- AVG Volume (30 Days)
- ABLV 7.4K
- LTRN 154.8K
- Earning Date
- ABLV 01-01-0001
- LTRN 03-17-2025
- Dividend Yield
- ABLV N/A
- LTRN N/A
- EPS Growth
- ABLV N/A
- LTRN N/A
- EPS
- ABLV N/A
- LTRN N/A
- Revenue
- ABLV $130,087,189.00
- LTRN N/A
- Revenue This Year
- ABLV N/A
- LTRN N/A
- Revenue Next Year
- ABLV N/A
- LTRN N/A
- P/E Ratio
- ABLV N/A
- LTRN N/A
- Revenue Growth
- ABLV N/A
- LTRN N/A
- 52 Week Low
- ABLV $0.55
- LTRN $2.79
- 52 Week High
- ABLV $3.10
- LTRN $11.99
- Technical
- Relative Strength Index (RSI)
- ABLV 60.59
- LTRN 57.34
- Support Level
- ABLV $1.02
- LTRN $4.34
- Resistance Level
- ABLV $1.15
- LTRN $5.30
- Average True Range (ATR)
- ABLV 0.06
- LTRN 0.58
- MACD
- ABLV -0.00
- LTRN 0.06
- Stochastic Oscillator
- ABLV 87.50
- LTRN 45.83
About ABLV Able View Global Inc.
Able View Global Inc operates as a brand management partner of international beauty and personal care brands in China. It provides full-service solutions covering marketing plan, branding, digital and social marketing, omni-channel sales, customer service, overseas logistics, warehouse, and fulfillment. The firm generates revenue from product sales by distributing and selling cross-border products from various brand owners to Chinese consumers.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.